Travere Therapeutics is evolving into a kidney-focused specialty pharma with FILSPARI scale, an FSGS monopoly position, and patent-driven upside, but execution must keep pace with rising IgAN competition and tighter cash demands.
Overview
Travere Therapeutics is a commercial-stage rare disease biotech that has repositioned itself from a legacy genetic disease portfolio into a focused kidney franchise led by FILSPARI. **The core investment case is that FILSPARI is now a scaled commercial asset with accelerating adoption, evidenced by Q1 2026 sales of $105.2 million, up 88.2% year over year, and a record 993 new patient start forms.** That momentum is being reinforced by the April 13, 2026 full FDA approval in FSGS without nephrotic syndrome, where Travere currently holds a first-and-only approved position. In IgAN, competition is intensifying, but FILSPARI retains a differentiated non-immunosuppressive oral profile and benefits from a REMS simplification approved in August 2025 that lowered monitoring burden. **The May 2026 USPTO Notice of Allowance for an IgAN method-of-use patent, if issued and Orange Book listed, could protect sparsentan through October 2037, materially improving franchise durability.** Financially, Travere remains GAAP loss-making but reached first-quarter non-GAAP profitability in Q1 2026. The main debate is whether FILSPARI growth, FSGS penetration, and pipeline progress can outrun competitive IgAN crowding and offset cash demands from the $112.5 million civorebrutinib upfront payment and ongoing development spend.